510(k) Application ECP Health System August 22, 2005

Attachment

510(k) Summary

ECP Health, Inc.
ECP Health System Model 2005

Date Prepared: August 22, 2005
 Submitter's Name: ECP Health, Inc.

and Address 8416 Prairie Rose Lane

Fort Worth, TX 76123

3. Contact Person: Shamon Huang, M.S.

Vice President ECP Health, Inc. Tel: (817)253-2891 Fax: (817)292-8265

4. Device Name: ECP Health System Model 2005
Proprietary Name: ECP Health System Model 2005
Common Name: External Counterpulsation Device
Classification Name: Device, Counter-pulsating, External

5. Predicate Device: The ECP Health System Model 2005 is substantially

equivalent to S-TCT Health External Counterpulsation Device (FDA granted 510(k) clearance on May 30, 2003 --

K030587)

6. Device Description: ECP Health System Model 2005 is a positive and

negative pressure integrated, non-invasive medical device for performing external sequential counterpulsation. It is a microprocessor-controlled system that inflates and deflates three parts of air cuffs which compress vascular beds in the calves, lower thighs, and upper thighs /buttocks to achieve

the desired therapy.

7. Intended use: The intended use of the ECP Health System Model

2005 is for the treatment of patients with:

510(k) Application ECP Health System August 22, 2005

- (1). Stable or unstable angina pectoris.
- (2). Acute myocardial infarction
- (3). Cardiogenic shock
- (4). Congestive heart failure
- 8. Key difference between the current device and the predicate device:
- (1): Congestive heart failure has been added to the indications for use of the device
- (2): Unstable angina pectoris has been added to the indications for use of the device
- (3): A finger pulse oximetry function has been added to measure and display oxygen saturation.
- 9. Comparison of Technological Characteristics :

Technological and functional characteristics of the ECP Health System Model 2005 are essentially the same as those of the predicate device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 2 6 2006

ECP Health Inc. c/o Mr. Shamon Huang Vice President 8416 Prairie Rose Lane Fort Worth, TX 76123

Re: K052611

ECP Health System Model 2005

Regulation Number: 21 CFR 870.5225

Regulation Name: External Counter-Pulsation Device

Regulatory Class: Class III

Product Code: DRN Dated: March 10, 2006 Received: March 17, 2006

Dear Mr. Huang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

mmumator

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

Indications for Use

510(k) Number (if known): <u>K052611</u>
Device Name: ECP Health System Model 2005
Indications for Use:
The intended use of the ECP Health System Model 2005 is for the treatment of patients with:
 Stable or unstable angina pectoris. Acute myocardial infarction Cardiogenic shock Congestive heart failure
Prescription Use _yes AN Over-The-Counter Use (Part 21 CFR 801 Subpart D) R (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page of (Posted November 13, 2003)
(Division Sign-Off) Division of Cardiovascular Devices 510(k) Number k color l